BAR123, we need the company to make the decisions that anyone with new and vastly improved standard-of-care therapeutics would do: run 2 well-designed, fully powered P3 trials for each incredibly good molecule.
But, CM should stay where he is. And $800K per year is chicken feed if you are a CEO in NYC. I would say it is a bargain but it is only a bargain if the CEO makes the right decisions.
Market Data 
Markets 
AI
